Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Common Equity (2016 - 2025)

Historic Common Equity for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $505.8 million.

  • Ani Pharmaceuticals' Common Equity fell 99.47% to $505.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $505.8 million, marking a year-over-year decrease of 99.47%. This contributed to the annual value of $403.7 million for FY2024, which is 2147.88% down from last year.
  • Per Ani Pharmaceuticals' latest filing, its Common Equity stood at $505.8 million for Q3 2025, which was down 99.47% from $436.8 million recorded in Q2 2025.
  • Ani Pharmaceuticals' Common Equity's 5-year high stood at $514.1 million during Q4 2023, with a 5-year trough of $191.4 million in Q3 2021.
  • Its 5-year average for Common Equity is $389.3 million, with a median of $403.9 million in 2022.
  • Per our database at Business Quant, Ani Pharmaceuticals' Common Equity soared by 10866.76% in 2022 and then plummeted by 2147.88% in 2024.
  • Over the past 5 years, Ani Pharmaceuticals' Common Equity (Quarter) stood at $387.8 million in 2021, then rose by 4.14% to $403.9 million in 2022, then grew by 27.28% to $514.1 million in 2023, then fell by 21.48% to $403.7 million in 2024, then rose by 25.3% to $505.8 million in 2025.
  • Its Common Equity was $505.8 million in Q3 2025, compared to $436.8 million in Q2 2025 and $418.6 million in Q1 2025.